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Abstract
Overweight and obesity in youth is a worldwide public health problem. Overweight and obesity in childhood and
adolescents have a substantial effect upon many systems, resulting in clinical conditions such as metabolic syn-
drome, early atherosclerosis, dyslipidemia, hypertension and type 2 diabetes (T2D). Obesity and the type of body
fat distribution are still the core aspects of insulin resistance and seem to be the physiopathologic links common
to metabolic syndrome, cardiovascular disease and T2D. The earlier the appearance of the clustering of risk factors
and the higher the time of exposure, the greater will be the chance of developing coronary disease with a more
severe endpoint. The age when the event may occur seems to be related to the presence and aggregation of risk
factors throughout life.
The treatment in this age-group is non pharmacological and aims at promoting changes in lifestyle. However,
pharmacological treatments are indicated in special situations.
The major goals in dietary treatments are not only limited to weight loss, but also to an improvement in the qual-
ity of life. Modification of risk factors associated to comorbidities, personal satisfaction of the child or adolescent
and trying to establish healthy life habits from an early age are also important. There is a continuous debate on
the best possible exercise to do, for children or adolescents, in order to lose weight. The prescription of physical
activity to children and adolescents requires extensive integrated work among multidisciplinary teams, patients and
their families, in order to reach therapeutic success.
The most important conclusion drawn from this symposium was that if the growing prevalence of overweight and
obesity continues at this pace, the result will be a population of children and adolescents with metabolic syn-
drome. This would lead to high mortality rates in young adults, changing the current increasing trend of world-
wide longevity. Government actions and a better understanding of the causes of this problem must be
implemented worldwide, by aiming at the prevention of obesity in children and adolescents.
Introduction
The worldwide concept of metabolic syndrome in chil-
dren and adolescents is still a matter of discussion
mainly because studies on this age group are scarce. In
this Symposium of Metabolic Syndrome, Dyslipidemia,
Hypertension and type 2 Diabetes in Children and Ado-
lescents, organized by the Department of Metabolic
Syndrome of the Brazilian Society of Diabetes, many
aspects of those clinical conditions were widely dis-
cussed, covering diagnosis, early atherosclerotic lesions,
therapeutic management and non-pharmacological as
well pharmacological treatment. The increased risk of
development of comorbidities like dyslipidemia, arterial
hypertension and glucose intolerance were also dis-
cussed and the following question was pointed out for
the therapeutic management of each condition: When
should we treat these youngsters pharmacologically?
More than 150 health care professionals including phy-
sicians, nurses and dietitians attended this Symposium
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debate on this important issue.
Metabolic Syndrome Diagnosis in Children and
Adolescents
Several large epidemiology cohort studies have docu-
mented that obesity and metabolic syndrome are asso-
ciated with cardiovascular outcomes in adults, such as
myocardial infarction, cerebrovascular disease and sud-
den death [1]. In recent years, there has been a greater
concern about the presence of obesity and metabolic
syndrome in children and adolescents [2]. Upper Obe-
sity is the core aspect of insulin resistance and seems to
be the physiopathologic link common to metabolic
syndrome.
There is no consensus regarding the diagnosis of
metabolic syndrome in children and adolescents as
recently discussed by Mancini [3]. It is evident that each
component of the syndrome must be identified as early
as possible in order to prevent definitive lesions. The
question is how to do this and which cut-offs must be
adopted for this diagnosis.
The diagnosis of metabolic syndrome in children and
adolescents requires the assessment of the abdominal
circumference (or BMI), blood pressure, lipoproteins
and glycemia. While the value of waist circumference as
a measure of visceral adiposity remains somewhat
debated, an accepted measurement of waist circumfer-
ence by percentiles was established [4]. Nevertheless,
t h e r ei ss o m ec o n t r o v e r s yabout how to measure the
abdominal circumference in children and adolescents.
There are some proposals: one of which was published
in 1999 by Freedman - one of the authors of the Boga-
lusa study [4]. In this study the authors correlated the
90
th percentile of abdominal circumference with
increased levels of LDL cholesterol, glycemia, insulin
and diminished HDL levels. Limits were established and
the use of a table for abdominal circumference was pro-
posed (above the 90
th percentile, considered to be the
maximum normal limit).
Some people claim that metabolic syndrome in chil-
dren must be defined by BMI and not by circumference.
An adjusted BMI curve according to gender and age
was proposed to the Brazilian population, produced by
the group supervised by Monteiro & Conde from the
School of Public Health of the University of Sao Paulo
[5]. Despite the existence of this curve, even for the
matter of comparing studies, BMI curves adjusted by
the North-American CDC have been more widely used
[6]. Normal BMI varies according to the child’sa g e .
Thus, it is impossible to apply a BMI range of 18.5-24.9
to a 12 or 13-year-old child. Overweight is defined
as above the 85
th percentile and obesity above the 95
th
percentile (tables available at http://www.cdc.gov).
Nonetheless, with the launching of the WHO references
for children 5-19 years old, obesity is considered as
above the 97
th percentile or 2
nd SD or z score (available
at http://www.who.int/growthref).
Proposals for the Definition of Metabolic Syndrome in
Children and Adolescents
For a discussion about the various proposals for the
definition of metabolic syndrome in children, refer to
reference 3.
The definition considered most appropriate and which
was added to this SBD publication is the one proposed
by the IDF. It divided children into age groups. There
was not a well defined proposal for children under
6 years of age, due to the lack of data. Unlike the cri-
teria presented above, for a matter of convenience, the
cut-offs in this proposal were fixed for pressure, lipids
and glucose, and abdominal circumference points were
assessed by percentile. In children aged 6-10, the cut-
offs for metabolic and blood pressure variables were not
well defined, therefore, only adiposity levels were evalu-
ated (considering abdominal circumference above the
90
th percentile). The same criteria would be used for
children aged 10-16; regarding glucose and lipid meta-
bolism, fasting glucose levels ≥100 mg/dl, triglycerides
≥150 mg/dl, HDL cholesterol below 40 mg/dl or the use
lipid lowering drugs were considered risk factors as well
blood pressure ≥130 or ≥85 mmHg. If the patient has
abnormal abdominal circumference and two more fac-
tors, the metabolic syndrome diagnosis is established.
The difference is that, for adolescents over 16 years of
age, there is a distincition between HDL ≤ 40 for men
or ≤ 50 for women, as described in Table 1.
The IDF criteria, though more convenient, fail to
include some children in the diagnosis of Metabolic
Syndrome. On the other hand, it would be easier to
accept as it does not use multiple tables to assess several
anthropometric and metabolic criteria [7].
Atherosclerosis in Young Adults
The acknowledgement of the presence of atherosclerotic
disease in young adults was demonstrated in necropsy
studies of American soldiers who were victims of the
Vietnam War. The lesions found in these individuals
varied from the presence of foam cells and fatty stretch
marks to type 4 lesions, i.e., mature atherosclerotic pla-
ques, with a well developed lipid core and the presence
of cholesterol and inflammatory cell crystals [8]. Based
on these findings and on the findings of other studies, it
was possible to certify that young individuals may
already present advanced atherosclerotic lesions. Studies
then continued to even lower age ranges, such as chil-
dren and adolescents, where atherosclerotic evidence
was also demonstrated. In this scenario, the Bogalusa
Halpern et al. Diabetology & Metabolic Syndrome 2010, 2:55
http://www.dmsjournal.com/content/2/1/55
Page 2 of 20Study stands out: approximately 12,000 children and
adolescents were prospectively and longitudinally fol-
lowed up. The authors analyzed the prevalence of the
main cardiovascular risk factors (RF) and observed that
they recurred throughout life, in a phenomenon known
as “tracking”, i.e., if they were present during early age,
they were more likely to persist throughout life [9].
About 190 of these individuals died from different
causes and were submitted to necropsy, and the pre-
sence of fibrous plaques in the aorta and coronary
arteries was described, confirming that atherosclerosis
was present since a very early age. Researchers also
found that lesions were increasingly severe according to
more advanced age and in the presence and/or aggrega-
tion of cardiovascular risk factors. Among present risk
factors in this cohort, obesity and systolic (but not dia-
stolic) blood pressure stood out, either alone or com-
bined, as the most correlated factors to the presence of
aortic and coronary atherosclerotic lesions. The majority
of complex lesions were associated with total cholesterol
levels, LDL levels and less intensely with triglyceride
levels. Smoking was also an important determining fac-
tor of early and accelerated development of athero-
sclerotic disease in these individuals [10]. Another study,
also conducted with children and adolescents, the
Pathobiological Determinants of Atherosclerosis in Youth
(PDAY) also demonstrated that the aggregation of cardi-
ovascular risk factors increased the risk of developing
atherosclerotic disease, detected on the intimal vessel
surface during necropsy studies [11].
These findings motivated researchers to conduct long-
itudinal studies on children and adolescents in an
attempt to detect the prevalence of the different cardio-
vascular risk factors. Among these, the Estudo do Rio de
Janeiro has been following up a cohort of over 3000 stu-
dents of both genders, aged 6-15, for over 17 years, aim-
ing at building blood pressure (BP) normality curves for
such individuals. The prevalence of the different cardio-
vascular risk factors was analyzed in a subgroup made
up of 365 children and adolescents and it was found to
be 14.6% for arterial hypertension, 21.6% for overweight
and/or obesity, 39.6% for dyslipidemia and 14.8% for
smoking [12]. Similar studies conducted in the USA
reported prevalence percentiles of 5-20% for hyperten-
sion, 20-33% for overweight/obesity, 13-35% for dyslipi-
demia and 25-35% for smoking [13]. Remarkably, such
prevalence is very similar to that found in adults.
The continuum concept presented by Dzau et al.
advocates that cardiovascular disease seems to develop
slowly from early stages until the clinical outcome,
which is frequently lethal. The earlier the appearance of
cardiovascular risk factors and the greater the time of
exposure, the higher the chance of developing the dis-
e a s ea n dt h em o r es e v e r et h ef i n a le n d p o i n ti s .T h ea g e
at which the event may occur seems to be related to the
presence and aggregation of cardiovascular risk factors
in the course of life [14].
The aggregation of several cardiovascular risk factors
in the same individual has been exhaustively demon-
strated in all age ranges. Miura et al. showed the asso-
ciation between blood pressure and mortality from
atherosclerotic disease in young adults in a 30-year
follow up study. The authors observed that, for each
10 mmHg increase in systolic blood pressure, there was
a 1.5% increase in mortality [15]. More recently, McCar-
ron et al. demonstrated that cardiovascular risk doubled
for each 20-mmHg increase in systolic blood pressure
and for each 10-mmHg in diastolic blood pressure [16].
Once the problem is identified, the crucial concern is
about which procedure needs to be adopted with a child
who has cardiovascular risk factors There are still few
intervention studies about this age range and the general
recommendation is to intensify efforts in order to cor-
rect risk factors and/or the presence of comorbidities
with non-pharmacological measures. There is no long
term study which confirms the safety of prolonged drug
use, in this age range, for the treatment of hypertension,
dyslipidemia, obesity and diabetes among others. How-
ever, considering the individual risk of children, pharma-
cological treatment has been frequently recommended
Table 1 Classification of metabolic syndrome in children and adolescents [3]
Criteria/
components
Age
6 to < 10 years-old 10 to 16 years-old > 16 years-old
Adiposity
definition
WC ≥ 90
th percentile WC ≥ 90
th percentile WC ≥ 90 cm (boys) or ≥ 80 cm (girls)
Glucose
metabolism
Without cut-off definition for
MS diagnosis
Fasting blood glucose ≥ 100 mg/dl Fasting blood glucose ≥ 100 mg/dl
Dyslipidemia Without cut-off definition for
MS diagnosis
Tg ≥ 150 mg/dl or HDL-ch ≥ 40 mg/dl
or taking LLD
Tg ≥ 150 mg/dl or HDL-ch ≥ 40 (boys) or ≥ 50 mg/dl
(girls) or taking LLD
Arterial
hypertension
Without cut-off definition for
MS diagnosis
DBP ≥ 130 or SBP ≥ 85 mmHg or taking
AHD
DBP ≥ 130 or SBP ≥ 85 mmHg or taking AHD
WC: waist circumference; MS: metabolic syndrome; Tg: triglyceride levels; HDL-ch: HDL-cholesterol levels; LLD: lipid-lowering drug; DBP: diastolic blood pressure;
SBP: systolic blood pressure; AHD: antihypertensive drug.
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symposium.
Nutritional Guidance for Children and
Adolescents with Metabolic Syndrome
The increasing prevalence of overweight and obesity in
youngsters has also been observed in Brazil. A recent
National study, the Nutri Brasil Infância,c o n d u c t e d
with 12 universities in the country showed that over
23% of Brazilian children present excess weight up to
the age of five - a fact that previously would have only
be seen in later age groups [17,18]. We have observed
an important increase in sedentary lifestyle and low phy-
sical activity levels in adolescents attending both public
and private schools. It is important to emphasize that
Brazilian children in general do not reach 30% of the
amount of moderate physical activity time per week sug-
gested by the World Health Organization, which would
be 150 minutes [19].
Considering non-pharmacological interventions for
treating children and adolescents with MS, promoting
lifestyle changes, which include increasing physical activ-
ity, eating balanced diets and engaging in psychosocial
approaches must be the initial step [20]. It is easier to
control meals at schools than at home. The main pro-
blem regarding diet control is how to reach a healthy
weight during a phase of such fast growth and gain of
both fat and lean mass. The major goals in dietary treat-
ments are not only limited to weight loss, but also to an
improvement in the quality of life, with the modification
of risk factors associated to comorbidities, personal
satisfaction of the child or adolescent and trying to
establish healthy life habits from an early age. This is
not a simple task, especially when our children live
among families with completely inadequate lifestyles and
eating habits [21]. Some goals that are well established
for adults will depend on age range, puberty stage and
gender when applied to children. For example, a 5 to
10% weight reduction, which is an exceptionally impor-
tant criterion of treatment success for adults, may not
be adequate for a child in growth and development,
especially in puberty. Regarding diets, the general goal is
to promote weight loss or stabilize the rate of weight
gain, reduce visceral fat, correct dyslipidemia and nor-
malize blood pressure [22]. These diets are generally
rich in fiber and low in saturated fat, cholesterol and
plain sugar content. Several types of diet allow weight
loss and the reduction of blood pressure levels, and con-
sequently minimize cardiovascular events [22]. However,
the major challenge is how to adjust these diets to such
a young population with habits which are so difficult to
change, who often follow the family’ss t a n d a r do f
inadequateness.
From a practical point of view, it is recommended that
food with high energy density be avoided, which pro-
motes the reduction of macronutrient imbalance. Some
discrepant aspects have been shown recently in our
field, such as avoiding milk and dairy products, recom-
mended by some groups. This is a conduct that contra-
dicts epidemiological evidence which relates greater
calcium intake to weight loss and a lower incidence of
cardiovascular events [23,24].
In 2007 [25], the American Medical Association
drafted a number of new measures and attempted to
resolve MS from the dietary and behavioral standpoint,
by establishing four phases of treatment:
Phase 1
global orientation for the child and the family. Simple
measures such as encouraging meals like breakfast and
others with the family could be useful. It is suggested
that meals outside of the home be limited and family
meals be encouraged, in order to allow the child to
reach self-regulation, moderating the use of restrictive
behaviors. In this phase, the goal would be to reduce
the rate of weight gain, thereby favoring growth. If the
child did not evolve properly, phase 2 would be the next
suitable step.
Phase 2
structured weight management programs designed by
trained primary health care professionals. These groups
would work with balanced diet plans, limiting high
energy density foods in the diets. In this phase, the goal
is to improve the structure of meals and snacks,
improve structured physical activity to at least 60 min-
utes per day, and reduce daily TV, video-game or com-
puter time to one hour or less. Data from research and
opinion institutes show that the use of electronic devices
by children in Brazil has reached an average of 4.8 hours
per day. The family needs to be monitored in all beha-
vioral aspects. The objective of this period is obviously
to reduce the BMI (body mass index). However, a
weight loss standard is still being determined: 450 g per
month for 2 to 11-year-olds, climbing up to almost 1 kg
for children and adolescents above 11 years old. If no
favorable result is seen at this point, the next step
would be phase 3.
Phase 3
Implementation of activities which include the monitor-
ing of food and physical activity, as well as short-term
goals for the diet, physical activity and change in beha-
vior must be performed with the help of a multidisci-
plinary team of specialists in childhood obesity,
professionals with experience in giving orientation about
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cal, educational and emotional support. For children
who remain above the 95
th percentile, with comorbid-
ities and who have not been successfully treated in the
previous phases, this phase must be tried. In this phase,
diet counseling is required beyond the general orienta-
tion: a more intense restriction on calorie intake is
established in association with an increase in continuous
physical activity. Additional strategies are established,
such as the use of food replacements, very low calorie
diets, and later the use of medications - leaving gastric
bypass surgery as a last possible intervention. Goals for
children of ages from 6 to 11, especially in overweight
children, are to maintain the weight until there is a pos-
sibility of recovery, or to get BMI rate to decrease. In
obese children, we should have a lower average of
weight loss. In severely obese individuals, weight loss
still cannot be higher than 1 kg per week, which is a
common barrier in most phase 3 healthcare programs.
However, we have to evaluate if these children who
enter programs of fat use restriction, carbohydrate
intake modification and most importantly, highly restric-
tive weigh loss counseling may present excessive weight
loss in the future, which could later result in eating dis-
orders and premature bulimia or anorexia.
In older children, an even greater caloric restriction
can be seen especially for the morbidly obese, consid-
ered as those above the 99
th percentile, or in other
words the third standard deviation or third Z score. It is
important to emphasize, that for children and adoles-
cents to reach a lifestyle change with nutritional educa-
tion and physical activity; it must be an ongoing effort
that should be started at an early age. We should think
that, without the adoption of dietary measures and the
implementation of change in the whole family’s life
style, the chance of reducing factors associated with
metabolic syndrome in children and adolescents will be
very small.
Physical Activity in Children and Adolescents - A
Realistic View
The increase in sedentary life over the last few decades
is closely linked to the increase in the prevalence of
overweight and obesity both in adults and children [26].
A survey conducted in London [27,28] has shown that
people walked 63 miles less in 2003 compared to 1975,
indicating a significant reduction in energy consump-
tion, which contributes considerably to weight gain in
adults as well as in children.
Regarding TV viewing, it has already been demon-
strated that watching television, regardless of age,
increases BMI, mainly in the group that watched TV for
over three hours a day [29]. A key concern is that, in
general, watching television is associated with higher
food consumption. A study conducted in Brazil has
shown that, during the times of day when children
watch television, advertisings are fundamentally about
the group of fats, sugars and sweets; therefore, children
are encouraged to ingest high calorie foods [30]. An epi-
demiological assessment conducted with Hispanic
Americans in Houston, Texas, has shown that obese
and thin children and adolescents had low physical con-
ditioning, which was even lower in the obese and in
girls [31]. Another interesting fact shown by this study
was that physical activities are different among boys
(more intense activities) and girls (light and moderate
activities). Physical activity changes from birth up to
18 years of age, and in general, girls practice less physi-
cal activity than boys, which is probably related to worse
results in terms of weight loss with physical activity in
women [32].
Regarding cardiovascular risk factors related to excess
weight and metabolic syndrome in children and adoles-
cents, different studies have shown that, at any age, the
number of risk factors is inversely related to physical
activity and to physical conditioning [33,34].
A meta-analysis was conducted with a systematic
review of over 600 studies: out of the 14 selected with
supervised exercises, four compared aerobic activity to
controls, nine compared the effects of diet therapy and
behavior therapy with and without aerobic and resis-
tance exercises. Weight reduction of about 2.7 kg was
observed, favorable to combined intervention, and up to
4 kg, when it was higher in intensity and length [35].
The regular practice of exercise results in a change in
body composition and several physiological and meta-
bolic benefits. In a study conducted in São Paulo, a one-
year intervention with physical activity and diet in obese
adolescents, visceral fat loss was observed over time
both in boys and in girls [36]. In Curitiba, a study group
assessed the influence of dietary counseling and physical
activity (three times a week), over a 24-week period on
64 obese adolescents. The study demonstrated a reduc-
tion in BMI and in waist circumference in both girls
and boys, but with greater responses in boys. In obese
adolescents with metabolic syndrome, there was also an
improvement in cardiovascular risk factors such as a
decrease in blood pressure, triglyceride levels, glucose
levels and in insulin resistance (determined by HOMA-
R), as well as an increase in HDL-cholesterol levels [37].
It was also noted in this study that, the reduction in
insulin resistance was associated to weight loss. How-
ever, even in adolescents who did not lose weight, there
was an improvement in insulin sensitivity through phy-
sical activity, probably resulting from metabolic condi-
tioning. Physical activity is able to improve insulin
sensitivity in a single exercise session, due to the
increase in glucose uptake by the muscle, but it returns
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In order to obtain proper metabolic conditioning, exer-
cise must be practiced regularly [38].
In addition to reducing risk factors, exercise promotes
changes in other factors. It improves endothelial func-
tion; decreases proinflammatory cytokine levels; reduces
stress levels in adults, children and adolescents; pre-
serves lean muscle mass in weight loss programs and
improves appetite control in previously sedentary indivi-
duals[39,40].
There is ongoing debate about the best exercise for
children or adolescents to lose weight. In this age range,
specific recommendations for physical activity - type,
intensity, length and frequency - vary widely. The pre-
s c r i b e de x e r c i s et y p ea n d“dosage” for a certain indivi-
dual will depend on the goal to be reached, i.e., losing
weight, controlling comorbidities, physical conditioning,
preventing obesity and weight recovery [41].
It has been suggested that in order to obtain beneficial
health effects, mainly in order to reduce cardiovascular
risk factors, school-age children should participate in
daily moderate to intense physical activities, for 60 min-
utes or more, as well as reducing sedentary behavior to
less than two hours a day [42,43]. However, several stu-
dies have shown that both obese children and adoles-
cents respond well to 30-40 minutes of physical activity,
3 times a week, improving cardiovascular conditioning
and the metabolic syndrome components such as hyper-
triglyceridemia, hyperinsulinemia and arterial hyperten-
s i o n ,e v e ni fw e i g h tl o s si sm i n i m a l ,a sl o n ga st h e
intervention is continuous and combined with good
dietary counseling [44,45]. The most indicated exercise
for weight loss and to reduce metabolic changes is aero-
bic exercise (jogging, swimming, cycling and other lei-
sure activities [42].
Physicians must pay attention, as adolescents change
their mind all the time, and they must practice the type
of physical activity they decide to, and switch it when-
ever they want. Very often, patients do not want or do
not like doing exercise. It is necessary to identify the
restraints which keep adolescents from participating in
activities [46-48]. It is important to emphasize to
patients and their family that exercise does not have to
be competitive, and that the main goal is to improve
physical conditioning, to reduce weight and comorbid-
ities. The compliance to physical exercise, at this age
range is the same as in adults, i.e., 20 to 80%. Fre-
quently, obese children or adolescents have low physical
conditioning. Their perception of effort is higher than
the perception of thin individuals, and skeletal muscle
pains are common, as a result of excess weight [49].
Therefore, it is important to establish progressive goals
(mainly regarding intensity and volume of activities)
until each patient meets the goals assigned to them.
Encouraging them to keep a diary recording the number
of hours spent watching TV, at the computer or playing
games and the frequency of physical activity also helps
the follow-up process. Obesity is a chronic disease
which affects individuals of all age ranges and is difficult
to handle. Lifestyle changes are essential for the treat-
ment to succeed. Among such changes, reducing seden-
tary life and practicing regular physical activity stand
out, mainly during childhood and adolescence, when
therapeutic pharmacological options are difficult.
The prescription of physical activity to children and
adolescents requires extensive integrated work among
multidisciplinary teams, patients and their families, in
order to reach therapeutic success.
Pharmacological Treatment of Obesity in Children
and Adolescents
The pharmacological treatment of obesity in children
and adolescents has as its main difficulty in the fact that
studies showing evidence about most drugs available in
the market are lacking for such age group. At present,
the drugs available for the treatment of obesity are: sibu-
tramine, orlistat and catecholaminergic agents (diethyl-
propione, fenproporex and mazindol) [50] The choice
criterion for which drugs to treat obesity with at such
an age range follows the same standards suggested for
the treatment of adults. In the case of food compulsion
or lack of satiety, sibutramine is the most indicated drug
[51]. Orlistat is more frequently indicated when there is
excessive food intake, including high-fat diets. In order
to use this drug, the absence of severe gastrointestinal
disease must be confirmed [52]. Regarding catecholami-
nergic agents, there is no global experience, not even in
adults, with relevant scientific studies. It can be indi-
cated for attention-deficit disorder [50], which is not
uncommon in obese children, because diethylpropione
and fenproporex have structural similarities to methyl-
phenidate, the drug of choice for this disorder. Thus,
when it comes to obese children with attention-deficit
disorder, rather good results may be obtained with
diethylpropione, fenproporex and even mazindol,
although it is a drug with no phenylethylamine nucleus.
Topiramate is a drug which has already been tested for
obesity [53], with good results, but due to side effects
has not been released in the market for such a purpose.
However, it has been increasingly used, mainly on indi-
viduals with mood disorders and food compulsion and
it is important to emphasize that it is contraindicated
for patients with a history of kidney stones. Bupropion
is one of the drugs of choice for tackling tobacco addic-
tion, but it may also work as an anti-obesity drug [54],
although contraindicated for epileptics. Fluoxetine is a
serotonin reuptake inhibitor which may help treat obe-
sity [3], particularly when associated with arterial
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are bipolar disorders and epilepsy. It can be inferred
that the drug choice will depend on the patient’s
personality, behavior, dietary habits and associated dis-
eases [55].
There are a few studies with metformin (a drug which
increases hepatic insulin sensitivity) in obese non-dia-
betic and insulin-resistant adolescents, demonstrating
that it may be a useful drug to fight obesity in children
[56-58]. The longest was a year-long study which
demonstrated reduced BMI and insulin resistance mea-
sured by HOMA-R in 28 obese adolescents with a dose
of 2 g of metformin per day [58].
In an orlistat placebo-controlled study which included
539 obese adolescents, followed for 12 weeks, it was
observed that associated risk factors improved and there
was variable weight loss, up to 15 kg in some cases,
with reduced insulin levels [7]. A 12-week study [59]
also showed important results in all associated comor-
bidities; on the other hand, the concern with gastroin-
testinal effects in children seems unjustified, as
according to such studies and to our experience, they
d on o ts e e mt ob em o r es e v e r et h a ni na d u l t s .T h e
weight-independent effects of orlistat are described as
improvements in cholesterol and hepatic enzyme levels,
lower increments of postprandial triglyceride levels and
increased insulin sensitivity [9].
Two important sibutramine studies have been con-
ducted with obese adolescents and published in litera-
ture. One of them was conducted in Brazil [60] for
12 weeks and demonstrated important results in weight
reduction when compared to placebo. The other study
included 498 obese adolescents, followed for 12 months,
and showed equally important weight-related results
and co-morbidity improvements with sibutramine [61].
Its side effects in adolescents were the same and at a
similar proportion to events reported by adults [51].
Taking into account the studies so far including chil-
dren and adolescents, the use of metformin, orlistat and
sibutramine is indicated starting from 10 years of age
(for type 2 diabetes treatment), 12 years of age and
16 years of age (for obesity treatment), respectively.
However, this does not mean that pharmacological
t r e a t m e n tm u s tn o tb eu s e di nl o w e ra g eg r o u p s .I n
severe cases of obesity, when health risks are extremely
evident, the aim is to prevent early co-morbidity and
mortality.
Dyslipidemia
Dyslipidemia in children and adolescents has become a
frequent clinical condition, especially due to the increase
in overweight and obesity prevalence in this age range
[62]. Treatment depends on the type of dyslipidemia,
i.e., if the cause is familial, with clinical signals such as
xanthomas or if dyslipidemia is inserted in the global
picture of metabolic syndrome. The lipid profile is com-
pletely diverse: while in familial dyslipidemia there is
significant hypercholesterolemia with LDL-c levels possi-
bly over 400 mg/dl [63] in dyslipidemia associated with
metabolic syndrome, there is a higher trend of hypertri-
glyceridemia, low HDL-c levels, and LDL-c levels with-
out quantitative but rather qualitative changes, such as
small dense particles which are more atherogenic [64].
Dyslipidemia at this age range may have a genetic com-
ponent with or without the environmental component,
such as improper diet, familial hypercholesterolemia,
familial combined hyperlipidemia and hypertriglyceride-
mia, and there may be types of dyslipidemia which are
predominantly environment-related, but which may also
have a genetic component, and in such cases excess
weight or weight gain is extremely important [64].
Prognosis
The prognosis depends on the type of dyslipidemia, and
it is well established that hypercholesterolemia, in its
homozygotic form, is extremely severe [65] with a pre-
valence of 1/1 million. Male children usually of 15 years
of age may already present a coronary event or death.
The heterozygotic form has a prevalence of 1/500 [63].
Women have a better evolution with longer life expec-
tancy than men, most of whom have already been diag-
nosed with coronary disease by the age of 50 years
old [63].
For dyslipidemia associated with metabolic syndrome,
recent data [63] have shown that the presence of meta-
bolic syndrome during childhood is associated with the
development of coronary disease 25 years later, i.e., in
adulthood [66].
Lipid Profile Assessment
When should the lipid profile of children and adoles-
cents be assessed? The 2005 1
st Guideline for Athero-
sclerosis Prevention in Children and Adolescents [67]
recommends that every child over 10 years old assesses
their cholesterol levels (Table 2). It is still being dis-
cussed if the most indicated assessment would be by
capillary blood (simple trial) or by total venous blood
Table 2 Recommended lipid levels in adolescents up to
19 years old
Lipides Desired
(mg/dl)
Coterminous
(mg/dl)
Increased
(mg/dl)
TC (mg/dl) < 150 150 - 169 ≥ 170
LDL-c (mg/dl) < 100 100 - 129 ≥ 130
HDL-c (mg/dl) ≥ 45
TG (mg/dl) < 100 100-129 ≥ 130
TC: total cholesterol; LDL-c: LDL-cholesterol; HDL-c: HDL-cholesterol; TG:
triglycerides.
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tions are more important when children present any of
the risk factors listed below:
1. Family history of early atherosclerosis in parents,
siblings or grandparents (before 55 years old in men
and before 65 years old in women);
2. If parents have cholesterol levels > 240 mg/dl;
3. If children have other associated risk factors, such
as hypertension, obesity and saturated fat or trans fatty
acid rich diet;
4. Children who have other diseases which may be
associated with dyslipidemia, such as AIDS and
hypothyroidism;
5. Children who use drugs which may predispose
them to dyslipidemia, e.g., isotretinoin for acne;
6. Children who present clinical manifestations of dys-
lipidemia, even if they are not pathognomonic, such as
xanthoma and/or xanthelasma - they are strong indica-
tors - and occasionally the presence of repeated pan-
creatitis in children who have hypertriglyceridemia.
The new recently published American Guideline in
Pediatrics [68] brings some important differences
regarding treatment:
1. Always initiate the treatment with non-pharmacolo-
gical measures;
2. Age of starting pharmacological treatment reduced
from 10 to 8 years old;
3. If the child is healthy and does not present other
problems, the LDL-c level limit for pharmacological
treatment is 190 mg/dl;
4. If the child has important family history or two risk
factors, the LDL-c level limit decreases to 160 mg/dl;
5. If the child is diabetic, the limit LDL-c level is
130 mg/dl
However, the early pharmacological treatment moti-
vated an editorial published in New England [69]. The
author demonstrates concern with the use of drugs in
situations that could be reverted by intensifying lifestyle
changes.
Classification of Familial Hypercholesterolemia
Although most of this review focuses on metabolic syn-
drome, we also need address hypercholesterolemia in
children.
Several mutations in several locations could result in
familial hypercholesterolemia, such as: mutation in the
LDL receptor [10], mutation in Apo B-100 [70] and
mutation in protease PCSK-9, which destroys LDL
receptors decreasing their half-life [70]. A certain muta-
tion of such protease would result in longer receptor
half-life with lower prevalence of coronary disease [71].
Recently, such a mutation was identified in black and
Caucasian populations, but the effect observed in the
black population was more intense. They have LDL-c
levels approximately 30% lower than those observed in
the average New York population; at the same time,
they presented 88% lower cardiovascular mortality rates.
Considering the pharmacological intervention studies,
for each mg/dl of LDL-c level reduction observed with
the treatment, it is possible to decrease the prevalence
of coronary disease by about 1%. Thus, we may infer
that in this NY population, the lowest mortality rate was
superior to the expectations of the lowest LDL-c levels
[71]. It is believed [72] that such a difference is due to
the fact that the low LDL-c levels observed in this popu-
lation have been the same in these individuals since
birth, different from the treatment with statins which
was usually initiated in clinical studies, in adulthood.
Diagnosis of Familial Hypercholesterolemia
For the diagnosis of familial hypercholesterolemia, two
non-exclusive but complementary strategies may be
used: 1) Cascade trial - which in selected cases are
researched due to personal and/or family history. In a
case of hypercholesterolemia or early coronary disease
(men under 55 years old and women under 65 years
old), descendants and family members are called for a
lipid profile assessment. In such cases, the new Ameri-
can Guideline already recommends the trial in one-year-
olds [68]. 2) Generalized trial - all children are assessed.
Considering the difficulties in obtaining the genetic
diagnosis, if children present LDL-c levels over 95 per-
cent for their age range and gender and if there is family
history of early coronary disease, the diagnosis is prob-
ably familial hypercholesterolemia[68], and the treat-
ment is often initiated immediately, especially in cases
of tendinous xanthoma.
Treatment
1. Non-pharmacological, including diet, physical activity
and phytosterols.
2. Pharmacological
Cholestyramine has always been accepted as the
first-line therapy drug for children due to it being a
resin which is not absorbed in the intestines; its effect
is intestinal, not systemic. It may affect the absorption
of liposoluble vitamins, which may result in important
side effects in children. The main side effect presented
is intestinal obstipation, therefore it is better tolerated
by children than by the elderly [73]. Cholestyramine
has a reduced effect in decreasing LDL-c levels (<
19%), as every intestinal-acting drug tends to have a
diminished effect due to intestinal adjusting (when
cholesterol absorption decreases in the intestine, a chy-
lomicron particle with lower cholesterol levels is gen-
erated and as it reaches the liver, it stimulates a higher
expression of the LDL receptor in order to increase
cholesterol reception) [73].
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tin as the first-line drug for treating hypercholesterole-
mic children other than cholestyiramine [68]. The drug
ezetimibe acts specifically in cholesterol absorption,
decreasing LDL-c levels by 20%, further decreasing it
when associated with statin[74]; it may also be used
alone or in association.
Statins have been used in adults since 1987, but long-
term studies still need to be conducted regarding its
prescription to children and adolescents in order to
determine the safety of using it over 20 or 30 years and
if its continued use is associated with the improvement
of clinical endpoints [13]. Side effects are similar to
those observed in adults, and there has been no evi-
dence of change in the growth, sexual and cognitive
development curves [75-77], as the decrease in choles-
terol synthesis does not compromise hormonal synthesis
or brain development [78].
Using fibrate and nicotinic acid in children and ado-
lescents is recommended only in exceptional situations,
as with fenofibrate, which is used when non-pharmaco-
logical measures are ineffective at treating hypertrigly-
ceridemia [73]. However, further studies must still be
conducted regarding the use of these drugs for such an
age range [68].
Using statin presents other benefits, such as the
improvement in flow-dependant endothelial function
[79] and the improvement in the progression of the car-
otid intima-media thickness in individuals with familial
hypercholesterolemia. A study conducted in the Nether-
lands demonstrated that the treatment of familial
hypercholesterolemia, when initiated at 10 years old,
changes the perspective of individuals [78].
It is concluded that, for dyslipidemia in children and
adolescents, family history and all the risk factors must
be assessed in order to determine the best therapeutic
strategy which allow the goals established for their age
range to be reached, thus preventing clinical cardiovas-
cular endpoints.
Hypertension in Children and Adolescents
The global increase in the prevalence of obesity, which
has also affected children and adolescents, is favoring an
increase in blood pressure and therefore, the prevalence
of arterial hypertension [80]. The impact of weight gain
on blood pressure is not the same in all age ranges nor
is it between men and women. In the young male popu-
lation, divided into quartiles according to body mass
index (BMI), an increase in the prevalence of arterial
hypertension can already be seen in the second quartile.
The association of BMI and hypertension is greater
among men below 45 years of age and in this subpopu-
lation, 60% of the hypertension cases can be attributed
to excess weight.
In women under 45 years old, the impact of weight
gain on the prevalence of arterial hypertension is lower,
compared to men. Above this age however, an evident
association between BMI and hypertension prevalence
has been observed. It is likely that in women above
45 years old or in menopause, weight gain associated
with the accumulation of abdominal fat favors the
increased prevalence of hypertension.
Physiopathological Mechanisms Associated to Arterial
Hypertension in Metabolic Syndrome
The possible mechanisms that trigger arterial hyperten-
sion associated with metabolic syndrome are mainly
related to the presence of visceral fat, which results in
insulin resistance. The subsequent hyperinsulinemia
promotes the increase in sodium absorption by the kid-
neys, which favors arterial hypertension [81]. In addi-
tion, hyperinsulinemia also increases the sympathetic
activity, which contributes to the development of arterial
hypertension [81].The accumulation of visceral fat ele-
vates the activity in the renin-angiotensin system, due to
an increased production of angiotensinogen, which con-
sequently favors arterial hypertension [82,83]. Experi-
mental studies have yet indicated that leptin could be
another factor within the physiopathology of arterial
hypertension as it causes the sympathetic activity to
increase [84].
Arterial Hypertension Diagnosis in Children and
Adolescents
Arterial hypertension should be measured in every child
as of three years old, mainly when there are family risk
factors. The method of choice is auscultation. The child
should be in a sitting position and at ease, preferably
leaning against the backrest and with their feet sup-
ported; the right arm should be at the same level as the
heart and blood pressure should be taken on at least
three different occasions. The diagnosis of hypertension
if blood pressure is altered in these three occasions was
established. Systolic pressure is determined by the first
Korotkoff sound and the diastolic by the fifth sound. It
is important to notice the size and the location of the
cuff, which should cover 40% of the circumference of
the arm, mid length between the acromion and the ole-
cranon, and the stethoscope should be placed in the
cubital fossa. These recommendations are important for
measuring blood pressure adequately. The normal levels
of blood pressure are based on gender, age and percen-
tile of height and are presented in tables which can be
used to determine whether the individual is hypertensive
or normotensive [85]. Some programs are already avail-
able on the Internet. By inserting the child’sa g ea n d
height, as well as systolic and diastolic blood pressure,
the information on the percentile the child is in
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enables the determination of whether the child is hyper-
tensive or not.
Arterial Blood Pressure Monitoring in children and
adolescents shows an increase in systolic blood pressure
with age. Daytime blood pressure is more elevated than
nighttime blood pressure. Other similar studies have
shown that systolic blood pressure varies much more
than diastolic blood pressure with reference to age.
Considering that blood pressure changes constantly
throughout childhood and that there are modifications
of normal values depending on gender, age and height,
normal blood pressure in children is defined as systolic
or diastolic blood pressure below the 90
th percentile
[85].
Pre-hypertension is defined when the child presents
blood pressure between the 90
th and 95
th percentiles, or
in adolescents when blood pressure is greater than 120/
80 mmHg. Stage 1 of arterial hypertension is defined
when the child presents blood pressure between the 95
th
and 99
th percentile with the addition of 5 mmHg, and
stage 2 when the pressure levels are above the 99
th per-
centile with the addition of 5 mmHg [85].
An increase in blood pressure is associated with
lesions of target organs, which has been shown in the
Rio de Janeiro Study. This study demonstrated an asso-
ciation of BMI, increase in blood pressure and hypertro-
phy in the left ventricle, measured either in grams or by
the left ventricular mass index [86]. The comparison
between the hypertensive group (blood pressure scores
above the 95
th percentile) and normotensive group
(blood pressure values below the 50
th percentile) showed
a significant difference in the left ventricle mass in these
adolescents. A third group which presented variable
blood pressure, sometimes above the 95
th percentile and
sometimes below these values, presented intermediary
left ventricle mass which indicates that alterations in
target organs, from very early stages of blood pressure
level elevation, can already be observed.
Treatment
It is important to remember that arterial hypertension in
children and adolescents, even when associated with
obesity, demands investigation for the diagnosis of sec-
ondary hypertension because the younger the child and
the more elevated the levels of blood pressure, the
greater the chance of developing secondary
hypertension.
In the pre-hypertension phase (between the 90
th and
95
th percentiles, or blood pressure above 120/80
mmHg, but lower than the 95
th percentile in adoles-
cents), the recommendation is lifestyle [87] changes
which promote weight loss and the improvement of
insulin sensitivity.
Drug treatment is indicated for stage 1 hypertension,
or upon the presence of symptoms (headaches or light-
headedness) or when there is no response to the
immediate lifestyle changes for a period of at least six
months, especially when there is a family history of
hypertension or premature cardiovascular disease [85].
The goal of the therapy is to obtain blood pressure
levels below the 95
th percentile. However, in the pre-
sence of target organ lesions or other cardiovascular risk
factors - like type 1 diabetes (T1D) with nephropathy or
even T2D - the goal is to obtain levels below the 90
th
percentile.
In stage 2 hypertension, the goals are similar to those
described for stage 1. The treatment should also aim at
reducing cardiovascular morbi-mortality in the long run,
although no studies conducted with children show that
arterial hypertension treatment will result in morbi-mor-
tality reduction.
There is no consensus regarding the best pharmacolo-
gical agent to be used when initiating essential hyperten-
sion therapy in children. It is suggested that the smaller
dose be used, enough to be effective and that it does
not cause side effects. In choosing anti-hypertensive
drugs however, we should preferably choose those
which will not enhance insulin resistance, promote
weight gain (beta-blockers), or worsen glucose intoler-
ance (thiazide diuretics) or the lipid profile, and that are
able to control blood pressure for 24 hours. The pre-
sence of other cardiovascular risk factors should also be
considered such as microalbuminuria, which reflects a
systemic endothelial lesion not restricted to the glomer-
ulus, as well as a hypertrophy of the left ventricle.
Lifestyle change measures should always be implemen-
ted as early as possible, as it is easier for children to
change life habits. A controlled consumption of salt
from the early months of life is recommended, fighting
excess weight from the first year of life and always
encouraging the premature practice of physical activity,
along with healthy eating habits.
In drug treatments of hypertension associated with
metabolic syndrome, the mechanisms which generate
hypertension such as the increase in activity of the
renin-angiotensin system and sympathetic system as
well as the increase of sodium absorption, should be
interfered with if possible always with the aim of
decreasing cardiovascular morbi-mortality. The drugs
more widely used and their mechanisms of action are
listed below:
1. Angiotensin receptor blockers and converting
enzyme inhibitors (ACEIs) inhibit the renin-angiotensin
system and reduce cardiovascular mortality in adults. In
the ACEI class, the drugs suited for pediatric use are
benazepril, captopril, enalapril [88], fosinopril[89], lisino-
pril [90] and quinapril. These drugs are totally
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by women or teenage girls of fertile age, they must be
accompanied by the use of safe contraceptive methods.
It is always necessary to evaluate the levels of potassium
and creatinine during therapy and coughing is a fre-
quent side effect. The FDA in the United States has
approved the use of ACEIs in children over six years old
and for individuals with creatinine depuration above
30 ml/min, as this condition offers a lesser risk of
hyperkalemia. These drugs present advantages, when
used on adults, for individuals with insulin resistance, as
they are associated to a lower risk of diabetes onset [91].
The angiotensin II receptor blockers (ARBs) approved
for use by children are losartan and ibesartan. These are
also contraindicated during pregnancy and recommen-
dations are similar to doses described for ACEIs. Losar-
tan has the advantage of being available in suspension
formulation, although not in Brazil. The use of ARBs
can also be associated with a lower incidence of dia-
betes, and these agents can be used for long periods, as
they are very well tolerated, due to their effects being
similar to placebo.
2. Calcium channel blockers (CCBs) promote natriur-
esis and have a vasodilating action; amlodipine, felodi-
pine, isradipine and slow-release nifedipine are approved
for pediatric use. Amlodipine and isradipine are avail-
able, in the United States, ins u s p e n s i o nf o r m u l a t i o n ,
which favors its use by children.
3. Beta-blockers have been recommended for young
patients for a long time and the agents bisoprolol,
metropolol, propanolol, labetalol (alfa and beta) are
approved for use by children and adolescents. The effi-
cacy of metropolol was demonstrated in a clinical trial
involving 140 children, showing to be effective in the
2 mg/kg dose [92]. Non-cardioselective agents should
not be used in patients with asthma or heart failure, and
their heart rate defines the dose to be used. These drugs
can reduce the individual’s performance during physical
activity. These are not the most indicated drugs for dia-
betic patients using insulin as they favor hypoglycemia,
unless under specific indications. Also, in individuals
with insulin resistance, it has been shown that these
agents increase the incidence of diabetes [93].
4. Diuretics such as hydrochlorothiazide, clortalidone,
furosemide, espironolactone, trianterene and amiloride
can be used. Thiazides and sub-products, as well as fur-
osemide are more effective as anti-hypertensives than
espironolactone and trianterene. Experience with adults
has shown that the use of low doses of thiazides is effec-
tive as an antihypertensive. In association, diuretics have
the ability to increase the efficiency of other antihyper-
tensive agents which act by other mechanisms. Thia-
zides promote hypokalemia, an undesireable side effect,
as it worsens glucose intolerance. This effect is dose-
dependent and can be minimized if associated with a
renin-angiotensin system blocker, an ARB or an ACEI,
which favor potassium retention. Potassium-sparing
diuretics are less effective and caution is necessary
because when associated with ACEIs or ARBs, there is
an increased chance of hyperkalemia. Furosemide can
be indicated when edema is present, but can be useful
in young patients with resistant hypertension, associated
with other drugs, as well as in children with kidney
failure.
5. Blockers of the sympathetic nervous system, periph-
eral alpha and beta-blockers and centrally acting alpha
agonists such as clonidine, are considered in the treat-
ment of resistant hypertensi o no rw h e nc o m p l i c a t i o n s
present, such as kidney failure. Clonidine causes side
effects such as xerostomia, sedation and nasal obstruc-
tion. They are available in the American market in
transdermic preparation, and their abrupt interruption
could cause a hypertensive crisis due to an adrenergic
discharge. Peripheral blockers like prazosin and doxaso-
sin, are more widely used these days in association, and
their advantage is the non alteration of the metabolic
profile, as they even improve insulin sensitivity. The side
effects are syncope, especially after the first dose and
water retention. In the ALLHAT study, the use of
prazozin was associated with negative endpoints and
showed an increased incidence of heart failure.
6. Vasodilators like hydralazine and minoxidil are indi-
cated when the blood pressure cannot be controlled,
especially in children with kidney failure. These agents
can cause tachycardia and water retention, and the
concomitant use of diuretics may become necessary,
especially in kidney failure, as well as the use of beta-
blockers, for the reduction of heart rate. Hydralazine
can cause lupus-like syndrome and the prolonged use of
minoxidil can trigger hypertrichosis.
It can be concluded that anti-hypertensive treatment
in children and adolescents should follow a customized
plan according to the clinical condition and metabolic
profile of the patient, having the reduction of cardiovas-
cular morbimortality as the primary goal.
Type 2 Diabetes in Children and Adolescents
The prevalence of type 2 diabetes mellitus (T2D) in chil-
dren and adolescents has increased over the last 20
years in many countries and several ethnic groups [94].
In the USA, it has been indicated as an epidemic: 80%
of Caucasian diabetic children over 10 years old had
type 1 diabetes mellitus (T1D). On the other hand, 46%-
86% of Afro-American, Hispanic, Asian-descendant or
Amerindian-descendant children have been diagnosed
with T2D [95]. In Europe and South America, the pre-
valence of T2D in children and adolescents is lower
[96-99], but a German study showed that 2.5% of
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cose tolerance (IGT) or diabetes [100], while an Argenti-
nean study observed 1.6% of T2D and 7% of IGT in
obese children [101]. In Japan, from 1976 to 1997, a
ten-fold increase was observed in the presence of glu-
cose abnormalities at the pediatric age range, a process
which has been reverted through the adoption of public
policies aiming at improving dietary habits [102].
In Brazil, there are few data on T2D prevalence in the
young population. A study conducted in Fortaleza
assessed 720 school-age children and found that capil-
lary glucose levels were higher than normal in 8.3% of
young people from 14 to 19 years old, most of whom
were female [103]. At the childhood obesity clinic of
The Group of Obesity in Hospital das Clínicas (Univer-
sity of Sao Paulo), abnormal fasting glucose levels and/
or IGT were found, respectively, in 5% and 2.5% of the
population studied (personal communication by Sandra
M. F. Villares).
Pathophysiology
The etiology of T2D in children and adolescents is mul-
tifactorial, similar to the one affecting adults, involving
genetic and environmental factors; it results from the
combination of insulin action resistance and b cell func-
tion failure. Insulin resistance is strongly associated with
obesity, particularly central adiposity. This is believed to
be the first abnormality in diabetes, preceding insulin
secretion failure [104]. There is a 50% reduction in sen-
sitivity and approximately 75% lower first phase insulin
secretion in type 2 diabetic adolescents as compared to
controls of non-diabetic obese individuals [105]. Insulin
secretion failure seems to be more severe than the one
observed in adults.
In adolescents at high risk of diabetes, the transition
from normal tolerance to impaired glucose tolerance or
pre-diabetes is associated with quick weight gain and a
decrease in insulinogenic index, while the progression to
T2D correlates to greater weight gain, reduced insulin
sensitivity and a dramatic decrease in insulin secretion
[106]. In type 2 diabetic adolescents, the decrease in b
cell function, observed over 6 years of follow-up, was
approximately 15% per year with no significant changes
in insulin sensitivity [107]. Such loss of function is more
than double and faster than the one observed in adults
in the UKPDS study, which was 7% per year [108].
Additionally, T2D is commonly associated with other
factors related to insulin resistance, such as hyperlipi-
demia, hypertension and non-alcoholic hepatic steato-
sis[109].
Risk Factors for Type 2 Diabetes
The risk factors for T2D in young people include: family
history, race and ethnicity, obesity and a sedentary
lifestyle. The risk of developing T2D is 5 times higher
for individuals with first-degree relatives with T2D as
compared to controls of the same gender, age and
weight with no family history of diabetes [110]. Deter-
mining factors for such risk are already present in fetal
life.
The risk of metabolic syndrome during childhood was
higher when neonates were on the weight curve extre-
mities, i.e., large for gestational age (LGA) or small for
gestational age (SGA). Similarly, children born from
mothers with gestational diabetes mellitus have higher
risk of developing T2D in adulthood [111,112].
In the USA, as previously described, T2D is two to six
times more prevalent in African-American, Hispanic,
Asian-descendant and Amerindian-descendant popula-
tions than in non-Hispanic Caucasians [113].
Several studies show that obesity associated with insu-
lin resistance and T2D mellitus has largely increased in
populations which have westernized their lifestyle, i.e.,
which have started consuming high-calorie diets and
reduced physical activity [114].
Polycystic ovary syndrome (PCOS) and acanthosis
nigricans are conditions associated with insulin resis-
tance. A clinical study has shown that 30 to 32 % of
young women between 14 and 19 years old with PCOS
had impaired glucose tolerance [115,116]. Acanthosis
nigricans, a disorder related with the activation of insu-
lin receptors in the skin by insulin excess, is present in
90% of T2D children [115,117-119].
During puberty, there is a physiological peak of insulin
resistance around Tanner stages 2 and 4, which returns
to normality in early adulthood. Its peak occurred at
Tanner 3 in both sexes, and girls were more insulin
resistant than boys at all Tanner stages The diagnosis of
T2D in young people occurs more frequently during the
second decade of life, and the average age of diagnosis
is 13.5, coinciding with the physiological peak of insulin
resistance [29,31,120,121].
Classification and Diagnosis of Diabetes in Childhood
The criteria for diagnosing diabetes in childhood are
based on glucose levels and the presence of symptoms
[122]. There are three possibilities for diagnosing dia-
betes, which, in the absence of unequivocal hyperglyce-
mia symptoms, must be confirmed by dosages in
subsequent days, as follows:
1. Fasting glycemia > 126 mg/dl,
2. Post-overload glucose levels with 1.75 g/kg of anhy-
drous glucose up to 75 g dissolved in water, ≥ 200 mg/dl
3. Classic symptoms of diabetes and casual glycemia
≥ 200 mg/dl, where ‘casual’ is defined as any time of
day, not related to the last meal, and ‘classic symptoms’
include polyuria, polydipsia and unexplainable weight
loss.
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do not reach those established for diagnosing diabetes,
but they are too elevated to be considered normal and
must be classified as impaired fasting glucose levels (≥
100 mg/dl, but < 126 mg/dl) or impaired glucose toler-
ance, 2 hours after glucose overload, glycemic levels
above 140 mg/dl, but lower than 200 mg/dl.
On the other hand, images shown as type 1 diabetes
(T1D) stereotypes - skinny children, with abrupt clinical
condition - are characteristics that are no longer typical
of the condition. Approximately one quarter of T1D
patients may be obese at the moment of diagnosis. T1D
may be confirmed by the 90% presence of anti-pancrea-
tic antibodies at the moment of diagnosis, while the
other 10% may have T2D, MODY or other types of dia-
betes (Tables 3 and 4).
Research is recommended through antibodies dosage
in overweight or obese children over 13 years old with
clinical features of T1D mellitus, i.e., weight loss and
ketosis or ketoacidosis (Figure 1).
Moreover, investigating the C-peptide levels is indi-
cated for obese or overweight children over 13 years
old, who have evolved with significant worsening of gly-
cemic control during oral drug treatment. Plasma C-
peptide levels over 1 ng/mL one year after diagnosis are
highly suggestive of T2D [123,124].
It is recommended to assess all children and adoles-
cents considered at risk of T2D (Table 5), from 10 years
old or at early puberty stage, if first, and it must be
repeated every two years. Fasting glycemia is the initial
test recommended by the American Diabetes Associa-
tion, due to its easy performance and convenience; even
though data in literature show higher prevalence of
impaired glucose tolerance and diabetes when glycemic
curves are used for such assessments [123,125,126].
Clinical Condition of Children with T2D
Usually, typical T2D children or adolescents, similarly to
adults, have few symptoms. There is also an intense
family aggregation, as these children frequently have
obese parents and first-degree relatives with T2D. Obe-
sity may be predominantly visceral, with clinical features
of metabolic syndrome and insulin resistance, such as:
hypertension, hyperlipemia, sleep apnea, polycystic ovary
syndrome and acanthosis nigricans. The initial condition
of T2D in children or adolescents may be of hyperos-
molar coma, currently known as the hyperglycemic
dehydration syndrome [119]. This syndrome may affect
up to 4% of the cases of T2D and presents mortality
rates from 14% to 43% [127]. These children are as
obese as adult type 2 diabetics, present change in level
of consciousness (Glasgow scale on average from 9 to
15, but the impairment might be even more severe),
average osmolarity of 400 mOsm and glycemic levels
around 600 mg/dl. Usually, even after metabolic com-
pensation, it may take from 1 to 7 days for the level of
consciousness to return to normal [128-130]. In 5% to
50% of the cases, T2D may manifest initially as diabetic
ketoacidosis [127,131].
Treatment of Children with T2D
T2D treatment goals in children and adolescents are:
reducing weight gain; maintaining linear growth;
increasing physical activity; normalizing glucose levels
and controlling comorbidities, including hypertension,
dyslipidemia and hepatic steatosis.
Table 3 Classification of Diabetes Mellitus in Children and Adolescents
T1D T2D ADM MODY
Age at onset Childhood Puberty Puberty Puberty
Severity at onset Acute/severe Moderate to severe, usually
insidious
Acute/severe Mild/insidious
Insulin secretion Very low Varying Moderately low Varying
Insulin sensitivity* Normal Reduced Normal Normal
Insulin dependency** Permanent No Varying No
Genetic Polygenic Polygenic Autosomal
dominant
Autosomal
dominant
Ethnic and racial distribution All (less frequent in
Asians)
Blacks, Hispanics, Asians and
Amerindians
Blacks Caucasians
Frequency (of all DM types in children and
adolescents)
~80% 10 - 20% 5 - 10% Rare
Association with
Obesity
No Strong Varying No
Acanthosis nigricans No Yes No No
Autoimmunity Yes No No No
DM: diabetes mellitus; T1D: type 1 diabetes mellitus; T2D: type 2 diabetes mellitus; ADM: atypical diabetes mellitus; MODY: maturity-onset diabetes of the young
or monogenic diabetes.
* insulin sensitivity: considered a pathogenic factor. **insulin dependency is diagnosed in the absence of acute disease or other stress factors [119].
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Page 13 of 20Table 4 Distinguishing features of type 1 and type 2 diabetes mellitus
T1D T2D
Start Abrupt and symptomatic Slow consolidation, with few symptoms
Family history 5% T1D 75-100% T2D
Insulin resistance uncommon common
Obesity Obese, normal or thin Typically present
Polidypsia, poliuria symptomatic Usually absent or mild
Ketoacidosis 30-40% at diagnosis 5-25 % at diagnosis
Hypertension and hyperlipemia - +
Sleep apnea - +
Acanthosis nigricans - +
Polycystic ovary - +
C-peptide levels Low Normal or elevated
Anti-pancreatic antibodies + (70-90%) Absent
Acanthosis nigricans - +
T1D: type 1 diabetes; T2D: type 2 diabetes.
Figure 1 Clinical classification of diabetes mellitus in children. *No-specific autoimmunity; ** Autosomal dominant (AD) family history (FHx)
of diabetes (DM) with an onset before 40 years of age;*** HGNK: hyperglycemia-nonketotic
+Autosomal dominant (AD) family history (FHx) of
diabetes (DM) in more than three generations.
++ Maturity-onset of diabetes of the young. Adapted from Rosenbloom, AL(127).
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and physical exercise), if results are not within the
guideline targets for the specific age range, the introduc-
tion of metformin is recommended at half the dose
usually prescribed to adults, increasing progressively up
to 2/3 of the maximum dose recommended for the
adult population [132,133]. Metformin decreases hepatic
glucose production and increases glucose capture by
peripheral tissues, as well as improving insulin resis-
tance, body composition, insulinemia and, in type 2 dia-
betic adolescents with polycystic ovaries, improves
SHBG and androgenic levels [42,44]. While prescribing
it to adolescents with ovulation disorders, the need for
contraception must be considered, as there is a possibi-
lity of inducing ovulation and unplanned pregnancy.
Metformin reduces glycosylated hemoglobin by up to
1.2%, and abdominal pain is the most common side
effect, affecting 25% of children [134,135].
If glycemic control is not achieved by lifestyle changes
and metformin in monotherapy, the next therapeutic
option would be sulfonylurea. It is known that these
drugs increase both basal insulinemia as insulin secre-
tion stimulated by food ingestion, leading to weight gain
and higher risk of hypoglycemia [47]. The maximum
dose recommended for children and adolescents corre-
sponds to 2/3 of the maximum dose for adults and the
reduction in glycosylated hemoglobin is approximately
0.8% [123]. Sulfonilureas (e.g., glibenclamida, glicazida,
glimepiride) act by increasing both basal and meal-sti-
mulated insulin secretion these obsviously carry the side
effects of increasing weight gain and risk of hypoglyce-
mia. There are no data regarding the appropriate man-
agement of type 2 diabetes in childhood.
Introducing insulin is indicated when the glucose level
targets have not been reached through dietary changes,
physical activity and oral agents in monotherapy or in
association. However, evidence shows that introducing
insulin early in the adult population makes long-term
glycemic control easier, which may perhaps revert
damage caused by hyperglycemia to b cells and insulin
sensitivity [136-138]. Other medications employed in
the T2D treatment of adults, such as glitazones, megliti-
nides, a-glucosidase inhibitor, amylin (pramlintide),
incretinomimetic (exenatide) and DPP-4 inhibitors (glip-
tins) are not approved for use in pediatric populations.
Insulin is the longest-standing and most effective
treatment for diabetes, because it is able to reduce
glycosylated hemoglobin (HbA1c) to normal levels.
However, the use of insulin is associated with weight
gain (2-4 kg), probably related to glycemic level correc-
tion and subsequent reduction in glycosuria, and
increased risk of hypoglycemia, due to high glycemic
control intensification, targeting HbA1c levels lower
than 7%. As advised by the latest ADA/EASD consensus
[139], basal insulin may be added to oral drugs (metfor-
min or metformin and sulfonylurea). Treatment is gen-
erally initiated by administering a medium-acting insulin
(NPH) or long-acting insulin analog (levemir or glar-
gine) dose of 0.1-0.2 U/kg of weight before bedtime, and
insulin dose adjustments must be made according to the
fasting capillary glycemic levels, measured on a daily
basis. The insulin dose must be increased by 2-4 units
every 3 days until reaching near-normal glycemic levels,
with no unexplainable hypoglycemia.
After correcting fasting glycemia, glucose monitoring
must be made at other times of the day, such as before
dinner: if levels are proper, it is possible to infer that
glycemic control goals have been reached. Another way
of assessing the effectiveness of treatment is through the
8-point profile, i.e., measuring capillary glycemia before
and after the 3 main meals, occasionally before bedtime
and during the night, as well as fasting glycemia the fol-
lowing day, in order to identify moments when glycemic
levels might be abnormal. It is suggested that measure-
ments be made once a week or every 15 days, on differ-
ent days of the week; however, this frequency may be
individualized, depending on whether or not metabolic
control is stable.
In the presence of hyperglycemia, when dieting errors
and improper oral therapeutics are excluded, it is sug-
gested to administer the second dose of NPH insulin
before breakfast, which must be a 4-unit dose, and to
maintain oral agents, progressively increasing the dose
according to self-monitoring. However, a few patients
may reach pre-prandial glucose targets and have hyper-
glycemia after meals, due to dieting errors or failure of
Table 5 Guidelines for investigating type 2 diabetes mellitus in children and adolescents with BMI > 85
th percentile
for age and gender or weight for age, gender and height > 85
th percentile or weight > 120% of ideal weight for
height (risk of obesity)
Presence of at least two risk factors
Family History T2D in 1
st and 2
nd degree relatives
Race/ethnicity* American Indian, Black, Hispanic, Asian or Pacific Islander
Signals or conditions associated with insulin resistance Acanthosis nigricans, arterial hypertension, dyslipidemia, polycystic ovary syndrome
Adapted: American Diabetes Association [123]. *In Brazil there are no data on race/ethnicity association as a risk factor for T2D, except for Asian adults.
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levels. If dieting errors are corrected by keeping similar
amounts of carbohydrates at each meal and postprandial
hyperglycemia still occurs, it is suggested to introduce
fast-acting or ultrafast-acting insulin before the “trouble-
some” meal, instead of an additional NPH insulin dose.
In such case, fast-acting insulin before meals is recom-
mended initially at a 4-unit dose, progressively increased
based on postprandial glucose levels.
Diabetes mellitus is an evolutionary disease with pro-
g r e s s i v er e d u c t i o ni nt h en u m b e ro fb cells able to pro-
duce insulin, leading to insufficient secretion of the
hormone and subsequent hyperglycemia, even in the
presence of oral drugs and insulin therapy [140,141]. In
this situation (beta-cell failure), intensive insulin therapy
is indicated, where basal insulin (multiple doses of NPH
or of long-acting analogs) is associated with fast-acting
or ultrafast-acting insulin before the main meals. The
therapy prescribed shall be basal-bolus insulin therapy,
similar to the one recommended for treating T1D
patients.
Complications
In this age range, T2D evolves with more comorbidities
than T1D [142,143]. Microvascular chronic complica-
tions, such as retinopathy, incipient nephropathy
(microalbuminuria) and peripheral neuropathy, and
macrovascular chronic complications are the most pre-
valent, and they decrease life expectancy and quality
[143]. Table 6 shows the comparison made between
young Australian populations under 18 years old with
type 1 and T2D. In relation to the complication rate at
diagnosis [142], results are similar to other populations
[144].
The prevalence of arterial hypertension and dyslipide-
mia is also much higher than in type 1 diabetic patients
who have had the disease for the same period of time; a
multicentric study conducted in the United States
observed that arterial hypertension was present in 10-
32% of young patients with T2D, and it is eight times
more frequent than in T1D individuals of the same age
[60]. Isolated or combined lipid changes were present in
24-44% of the cases, albeit only 1% of those children
were undergoing pharmacological treatment with dysli-
pidemia [144].
Microalbuminuria is another important risk factor
associated with T2D in children and adolescents, which
gets worse over the period of time the patient has the
disease [142,145-148]. Microalbuminuria is present in
14 - 25% at the moment of diagnosis; its incidence is
high during the decade following the diagnosis and is
linked to glycemic control. Additionally, microalbumi-
nuria in T2D young individuals prematurely evolves to
renal failure. During the follow up of Pima Indians with
youth-onset type 2 diabetes mellitus, the incidence of
diabetic end-stage renal disease was 5 times higher than
compared to those who developed diabetes after the age
of 20. Similar data were found in Japan when T2D diag-
nosis occurs before the age of 30 [149].
Apart from classic complications, the risk of non-alco-
holic hepatic steatosis, hepatic cirrhosis and portal
hypertension is five times higher in children with meta-
bolic syndrome [150-152]. Neuropsychiatric diseases are
also more prevalent in young type 2 diabetic individuals.
Levitt-Katz and colleagues [153] have demonstrated that
20% of those patients had some neuropsychiatric disor-
der such as depression, attention deficit disorder, hyper-
activity, neuropsychomotor development disorder,
schizophrenia or bipolar disorder. Sixty three per cent
of these patients were making use of antipsychotic
drugs, increasing the possibility of weight gain by using
such drugs, and the possibility of worsening metabolic
control by using atypical antipsychotic drugs [154,155].
In conclusion, T2D in children and adolescents is
associated with a high number of comorbidities and to
the occurrence of complications, deeply affecting the
quality of life of those individuals when they are still
young. The proper treatment and especially the preven-
tion must be attentively looked at by everyone involved
in caring for children at risk of T2D mellitus.
Acknowledgements
The authors would like to thank Marilia de Brito Gomes for providing
technical help and assistance in the organization of the manuscript.
Author details
1Group of Obesity and Metabolic Syndrome, Endocrinology and Metabolism
Service, Hospital das Clínicas da Faculdade de Medicina, São Paulo University
(HC-FMUSP). Av. Dr. Enéas de Carvalho Aguiar, 155 - 8º andar - bloco 3. São
Paulo, Brazil.
2Arterial Hypertension and Lipids Sector of Hospital
Universitário Pedro Ernesto - State University of Rio de Janeiro (UERJ). Rua
São Francisco Xavier, 524. Rio de Janeiro, Brazil.
3Adolescent Center,
Department of Pediatrics, Federal University of Sao Paulo (UNIFESP). Rua
Pedro de Toledo, 650, 2o andar. São Paulo, Brazil.
4Endocrinology and
Metabolism Service of Hospital de Clínicas, Department of Nutrition, Federal
University of Paraná (UFPR). Rua General Carneiro, 181. Curitiba, Brazil.
5Dante
Pazzanese Institute of Cardiology of the São Paulo State Health Department.
Av. Dr. Dante Pazzanese, 500. São Paulo, Brazil.
6Service of Endocrinology,
Department of Medicine, Federal University of São Paulo (UNIFESP). Rua
Pedro de Toledo, 650, 2º andar. São Paulo, Brazil.
7Group of Diabetes,
Endocrinology and Metabolism Service, Hospital das Clínicas da Faculdade de
Table 6 Chronic complication prevalence among type 1
and type 2 diabetes mellitus in children and adolescents
T1D (%) T2D (%) p
Microalbuminuria 6 28 < 0.001
Arterial hypertension 16 36 < 0.001
Retinopathy 20 4 0.43
Peripheral neuropathy 27 21 0.48
Obesity 7 56 < 0.001
T1D: type 1 diabetes; T2D: type 2 diabetes. Adapted from Eppens, MC et al
[142].
Halpern et al. Diabetology & Metabolic Syndrome 2010, 2:55
http://www.dmsjournal.com/content/2/1/55
Page 16 of 20Medicina, São Paulo University (HC-FMUSP). Av. Dr. Enéas de Carvalho
Aguiar, 155 - 8º andar - bloco 3. São Paulo, Brazil.
Authors’ contributions
AH: wrote the section about Pharmacological Treatment; MM and MEM:
wrote the section about Metabolic Syndrome Diagnosis in Children and
Adolescents, revised the manuscript and made the requested formatting
changes; MECM: wrote the section about Atherosclerosis in Young Adults;
MF: wrote the section about Nutritional Orientation in Children and
Adolescents with Metabolic Syndrome; RR: wrote the section about Physical
Activity in Children and Adolescent; MCB and AB: wrote the section about
Dyslipidemia; MTZ: wrote the section about Hypertension in Children and
Adolescents; MQ and MN: wrote the section about T2D in Children and
Adolescents.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 December 2009 Accepted: 18 August 2010
Published: 18 August 2010
References
1. Halpern A, Mancini MC: Treatment of obesity: an update on anti-obesity
medications. Obes Rev 2003, 4:25-42.
2. Weiss R, Dziura J, Burgert TS, et al: Obesity and the metabolic syndrome
in children and adolescents. N Engl J Med 2004, 350:2362-2374.
3. Mancini MC: Metabolic Syndrome in children and adolescents - criteria
for diagnosis. Diabetol Metab Syndr 2009, 1(1):20.
4. Freedman DS, Serdula MK, Srinivasan SR, Berenson GS: Relation of
circumferences and skinfold thicknesses to lipid and insulin
concentrations in children and adolescents: the Bogalusa Heart Study.
Am J Clin Nutr 1999, 69:308-317.
5. Conde WL, Monteiro CA: Body mass index cutoff points for evaluation of
nutritional status in Brazilian children and adolescents. J Pediatr 2006,
82:266-272.
6. BMI for Children and Teens :[http://www.cdc.gov/healthyweight/assessing/
bmi/childrens_bmi/about_childrens_bmi.html].
7. Cook S, Weitzman M, Auinger P, et al: Prevalence of a metabolic
syndrome phenotype in adolescents: Findings from NHANES-III, 1988-
1994. Arch Pediatr Adolesc Med 2003, 157:821-827.
8. Dietschy JM, Turley SD, Spady DK: Role of liver in the mintenance of
cholesterol and low density lipoproteins homeostasis in different animal
species, including humans. J Lipid Res 1993, 34:1637-1659.
9. Wattigney WA, Weber LS, Srinivasan SR, Berenson GS: The emergency of
clinically abnormal levels of cardiovascular disease risk factor variables
among young adults: the Bogalusa Heart Study. Prev Med 1995,
24:617-626.
10. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE,
Wattigney WA: Association between multiple cardiovascular risk factors
and atherosclerosis in children and young adults: The Bogalusa Heart
Study. New Engl J Med 1998, 338:1650-1656.
11. Mahan CA, Gill HC, Gidding SS, Malcom GT, Newman WP, Tracy RE,
Strong JP: PDAY risk score predicts advanced coronary artery
atherosclerosis in middle-aged persons as well as youth. Atherosclerosis
2007, 190(2):370-377.
12. Fonseca FL, Brandão AA, Pozzan R, Campana EMG, Pizzi OL,
Magalhães MEC: A Relação entre a pressão arterial e índices
antropométricos na infância/adolescência e o comportamento das
variáveis de risco cardiovascular na fase adulta jovem, em seguimento
de 17 anos: Estudo do Rio de Janeiro. Rev SOCERJ 2008, 21(5):281-290.
13. Morrison JA, Sprecher DL, Barton BA, Waclawiw MA, Daniels SR:
Overweight fat patterning and cardiovascular disease risk factors in
black and white girls: The National Heart, Lung and Blood Institute
Growth and Health Study. J Pediatr 1999, 135:458-464.
14. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ,
Stevenson W: The cardiovascular disease continuum validated: clinical
evidence of improved patient outcomes: Part I: Pathophysiology and
clinical trial evidence (risk factors through stable coronary artery
disease). Circulation 2006, 114(25):2850-2870.
15. Miura K, Daviglus ML, Dyer AR: Relationship of blood pressure to 25-year
mortality due to coronary heart disease, and all causes in young adult
men. Arch Intern Med 2001, 161:1501-1508.
16. McCarron P, Smith GD, Okasha M, McEwen J: Blood pressure in young
adulthood and mortality from cardiovascular disease. Lancet 2000,
355:1430-1431.
17. Bueno MB, Marchioni DM, Fisberg RM: Changes in the nutritional status of
children in public day care facilities in the municipality of São Paulo,
Brazil. Rev Panam Salud Publica 2003, 14(3):165-170.
18. Bernardi JR, Cezaro CD, Fisberg RM, Fisberg M, Vitolo MR: Estimation of
energy and macronutrient intake at home and in the kindergarten
programs in preschool children. J Pediatr (Rio J) 2010, 86(1):59-64.
19. Costa RF, Cintra Ide P, Fisberg M: Prevalence of overweight and obesity in
school children of Santos City, Brazil. Arq Bras Endocrinol Metabol 2006,
50(1):60-67.
20. Shetty P: Community-based approaches to address childhood
undernutrition and obesity in developing countries. Nestle Nutr Workshop
Ser Pediatr Program 2009, 63:227-257.
21. Figueiredo IC, Jaime PC, Monteiro CA: Factors associated with fruit and
vegetable intake among adults of the city of São Paulo, Southeastern
Brazil. Rev Saude Publica 2008, 42(5):777-785.
22. Srinath RK, Katan MB: Diet, nutrition and the prevention of hypertension
and cardiovascular diseases. Public Health Nutr 2004, 7(1A):167-186.
23. Ball GD, Lenk JM, Barbarich BN, Plotnikoff RC, Fishburne GJ, Mackenzie KA,
Willows ND: Overweight children and adolescents referred for weight
management: are they meeting lifestyle behaviour recommendations?
Appl Physiol Nutr Metab 2008, 33(5):936-945.
24. Zemel MB, Donnelly JE, Smith BK, Sullivan DK, Richards J, Morgan-Hanusa D,
Mayo MS, Sun X, Cook-Wiens G, Bailey BW, Van Walleghen EL,
Washburn RA: Effects of dairy intake on weight maintenance. Nutr Metab
(Lond) 2008, 24(5):28.
25. AMA Expert Committee - Appendix: Expert Committee Recommendations
on the Assessment, Prevention, and Treatment of Child and Adolescent
Overweight and Obesity. [http://www.ama-assn.org/ama1/pub/upload/
mm/433/ped_obesity_recs.pdf].
26. Obarzanek E, Schreiber GB, Crawford PB, et al: Energy intake and physical
activity in relation to indexes of body fat: the National Heart, Lung, and
Blood Institute Growth and Health Study. Am J Clin Nutr 1994, 60:15-22.
27. Hills AP: Youngsters: Lessons for Childhood Obesity. J Exerc Sci Fit 2009,
7(2):S28-S33.
28. Fox KA, Hillsdon M: Physical activity and obesity. Obes Rev 2007,
8(Suppl.1):115-121.
29. Proctor MH, Moore LL, Gao D, et al: Television viewing and change in
body fat from preschool to early adolescence: The Framingham
Children´s Study. Int J Obes 2003, 27:827-833.
30. Almeida SS, Nascimento PC, Quaioti TCB: Amount and quality of food
advertisement on Brazilian television. Rev Saude Publica 2002,
36(3):353-355.
31. Butte NF, Puyau MR, Adolph AL, Vohra FA, Zakeri I: Physical activity in non
overweight and overweight Hispanic children and adolescents. Med Sci
Sports Exer 2007, 39:1257-1266.
32. Goran MI, Gower BA, Nagy TR, Johonson RK: Developmental changes in
energy expenditure and physical activity in children: evidence for a
decline in physical activity in girls before puberty. Pediatrics 1998,
101:887-891.
33. Froberg K, Andersen LB: Mini review: Physical activity and fitness and its
relations to cardiovascular disease risk factors in children. Int J Obes
(Lond) 2005, 29:S34-S39.
34. Eisenmann JC: Aerobic fitness, fatness and the metabolic syndrome in
children and adolescents. Acta Paed 2007, 96:1723-1729.
35. Atlantis E, Barner EH, Fiatarone SMA: Efficacy of exercise for treating
overweight in children and adolescents: a systematic review. Int J Obesity
2006, 30:1027-1040.
36. Caranti DA, Mello MT, Prado WL, et al: Short- and long-term beneficial
effects of a multidisciplinary therapy for the control of metabolic
syndrome in obese adolescents. Metabolism 2007, 56(9):1293-1300.
37. Leite N, Milano GE, Cieslak F, Lopes WA, Rodacki A, Radominski RB: Effects
of physical exercise and nutrition guidance on metabolic syndrome in
obese adolescents. Rev Bras Fisiot (Sao Carlos) 2009, 13(1):73-81.
Halpern et al. Diabetology & Metabolic Syndrome 2010, 2:55
http://www.dmsjournal.com/content/2/1/55
Page 17 of 2038. Després JP, Lamarche B: Effects of diet and physical activity on adiposity
and body fat distribution: Implications for the prevention of
cardiovascular disease. Nutr Res Rev 1993, 6:137-159.
39. Woo KS, Chook P, Yu CW: Effects of diet and exercise on obesity-related
vascular dysfunction in children. Circulation 2004, 109(16):1981-1986.
40. Martins C, Morgan L, Truby H: A review of the effects of exercise on
appetite regulation: an obesity perspective. Int J Obes 2008, 32:1337-1347.
41. Baumer JH: Guideline review - Obesity and overweight: its prevention,
identification, assessment and management. Arch Dis Child Educ Pract
2007, 92:92-96.
42. Strong WB, Malina RM, Bumke JR, et al: Evidence based physical activity
for school-age youth. J Pediatr 2005, 146:732-737.
43. Andersen LB, Harro M, Sardinha LB, et al: Physical activity and clustered
cardiovascular risk in children: a cross sectional study - The European
Youth Heart Study. Lancet 2006, 368:299-304.
44. Nowicka P, Flodmark CE: Physical activity- key issues in treatment of
childhood obesity. Acta Paed 2006, 96:39-45.
45. Eliakim A, Kaven G, Berger I, et al: The effect of a combined intervention
on body mass index and fitness in obese children and adolescents - a
clinical experience. Eur J Pediatr 2002, 161:449-454.
46. Malina RM, Bouchard C: Strength and motor performance during growth.
In Growth, Maturation, and Physical Activity. Edited by: Malina RM, Bouchard
C. Champaign, IL: Human Kinetcs Publishers; 1991:187-204.
47. McWhorter JW, Wallmann HW, Alpert PT: The obese child: Motivation as a
toll for exercise. J Pediatr Health Care 2003, 17:11-17.
48. Robbins LB, Pender NJ, Kazanis AS: Barriers to physical activity perceived
by adolescent girls. J Midwifery Womens Health 2003, 48:206-212.
49. Daniels SR, Jacobson MS, McCrindle BW, et al: American Heart Association
Childhood Obesity Research Summit Report. Circulation 2009, 119:
e489-e517.
50. Halpern A, Mancini MC: Treatment of obesity - an update on anti-obesity
medications. Obes. Rev 2003, 4:25-42.
51. Lean MEJ: Sibutramine, a review of clinical efficacy. Int J Obes Relat Metab
Disord 1997, 21(Suppl 1):S30-S36.
52. McDuffie J, Calis K, Uwaifo G, et al: Three-month tolerability of orlistat in
adolescents with obesity-related co-morbid conditions. Obes Res 2002,
10:642-650.
53. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M: A randomized
double-blind placebo-controlled study of the long-term efficacy and
safety of topiramate in the treatment of obese subjects. Int J Obes 2004,
28:1399-1410.
54. Anderson JW, Greenway FL, Fukioka , et al: Bupropion SR enhances weight
loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002,
10:663-641.
55. Goldstein DJ, Rampey AH Jr, Enas GG, Potvin JH, Fludzinski LA, Levine LR:
Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J
Obes Relat Metab Disord 1994, 18(3):129-35.
56. Kay JP, Alemzadeh R, Langley G, et al: Beneficial effects of metformin in
normoglycemic morbidly obese adolescents. Metabolism 2001,
50:1457-1461.
57. Freemark M, Bursey D: The effects of metformin on body mass index and
glucose tolerance in obese adolescents with fasting hyperinsulinemia
and a family history of type 2 diabetes [abstract]. Pediatrics 2001, 107:E55.
58. Srinivasan S, Ambler GR, Baur LA, Garnett SP, et al: Randomized, controlled
trial of metformin for obesity and insulin resistance in children and
adolescents: improvement in body composition and fasting insulin. J
Clin Endocrinol Metab 2006, 91(6):2074-2080.
59. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J: Effect of orlistat
on weight and body composition in obese adolescents: a randomized
controlled trial. JAMA2005, 293(23):2873-2883.
60. Godoy-Matos A, Carraro L, Vieira A, et al: Treatment of obese adolescents
with sibutramine: a randomized, double-blind, controlled study. J Clin
Endocrinol Metab 2005, 90(3):1460-1465.
61. Berkowitz R, Wadden T, Tershakovec A, et al: Behavior therapy and
sibutramine for the treatment of adolescent obesity: a randomized
controlled trial. JAMA2003, 289(14):1805-1812.
62. Zimmet P, Alberti KG, Kaufman F, et al: The metabolic syndrome in
children and adolescents - an IDF consensus report. Pediatr Diabetes
2007, 8(5):299-306.
63. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA:
Familial hypercholesterolemia: current treatment and advances in
management. Expert Rev Cardiovasc Ther 2008, 6(4):567-581.
64. Steinberger J, Daniels SR, Eckel RH, et al: Progress and challenges in
metabolic syndrome in children and adolescents: a scientific statement
from the American Heart Association Atherosclerosis, Hypertension, and
Obesity in the Young Committee of the Council on Cardiovascular
Disease in the Young; Council on Cardiovascular Nursing; and Council
on Nutrition, Physical Activity, and Metabolism. Circulation 2009,
119(4):628-647.
65. Kolansky DM, Cuchel M, Clark BJ, et al: Longitudinal evaluation and
assessment of cardiovascular disease in patients with homozygous
familial hypercholesterolemia. Am J Cardiol 2008, 102(11):1438-1443.
66. Morrison JA, Friedman LA, Gray-McGuire C: Metabolic syndrome in
childhood predicts adult cardiovascular disease 25 years later: the
Princeton Lipid Research Clinics Follow-up Study. Pediatrics 2007,
120(2):340-345.
67. Back GI, Caramelli B, Pellanda L, Duncan B, Mattos S, Fonseca FH: I
Guidelines of Prevention of Atherosclerosis in Childhood and
Adolescence. Arq Bras Cardiol 2005, 85(Suppl 6):4-36.
68. Daniels SR, Greer FR: Lipid screening and cardiovascular health in
childhood. Pediatrics 2008, 122(1):198-208.
69. de Ferranti S, Ludwig DS: Storm over statins - the controversy
surrounding pharmacologic treatment of children. N Engl J Med 2008,
359(13):1309-1312.
70. Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of
familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007,
4(4):214-225.
71. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in
PCSK9, low LDL, and protection against coronary heart disease. N Engl J
Med 2006, 354(12):1264-1272.
72. Brown MS, Goldstein JL: Biomedicine. Lowering LDL - not only how low,
but how long? Science 2006, 311(5768):1721-1723.
73. Girardet JP: Anticholesteremic agents in children. Therapie 2003,
58(1):63-67.
74. Turley SD: Cholesterol metabolism and therapeutic targets: rationale for
targeting multiple metabolic pathways. Clin Cardiol 2004, 27(6 Suppl 3):
III16-III21.
75. Arambepola C, Farmer AJ, Perera R, Neil HA: Statin treatment for children
and adolescents with heterozygous familial hypercholesterolaemia: a
systematic review and meta-analysis. Atherosclerosis 2007, 195(2):339-347.
76. Gotto AM: Efficacy and safety of statin therapy in children with familial
hypercholesterolemia: a randomized controlled trial. J Pediatr 2005,
146(1):144-145.
77. Rodenburg J, Vissers MN, Trip MD, Wiegman A, Bakker HD, Kastelein JJ: The
spectrum of statin therapy in hyperlipidemic children. Semin Vasc Med
2004, 4(4):313-320.
78. Rodenburg J, Vissers MN, Wiegman A, et al: Statin treatment in children
with familial hypercholesterolemia: the younger, the better. Circulation
2007, 116(6):664-668.
79. Ferreira WP, Bertolami MC, Santos SN, et al: One-month therapy with
simvastatin restores endothelial function in hypercholesterolemic
children and adolescents. Pediatr Cardiol 2007, 28(1):8-13.
80. MacMahon SW, Blacket RB, Macdonald GJ, Hall W: Obesity, alcohol
consumption and blood pressure in Australian men and women - The
National Heart Foundation of Australia Risk Factor Prevalence Study. J
Hypertens 1984, 2(1):85-91.
81. Hall JE: The kidney, hypertension, and obesity. Hypertension 2003,
41:625-633.
82. Ailhaud G, Fukamizu A, Massiera F, Negrel R, Saint-Marc P, Teboul M:
Angiotensinogen, angiotensin II and adipose tissue development. Int J
Obes Relat Metab Disord 2000, 24:S33-S35.
83. Dusserre E, Moulin P, Vidal H: Differences in mRNA expression of the
proteins secreted by the adipocytes in human subcutaneous and
visceral adipose tissues. Biochim Biophys Acta 2000, 1500:88-96.
84. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and
sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S.
85. National High Blood Pressure Education Program Working Group on High
Blood Pressure in Children and Adolescents: The fourth report on the
Halpern et al. Diabetology & Metabolic Syndrome 2010, 2:55
http://www.dmsjournal.com/content/2/1/55
Page 18 of 20diagnosis, evaluation and treatment of high blood pressure in children
and adolescents. Pedriatics 2004, 114:555-576.
86. Brandão AA, Pozzan R, Albanesi Fº FM, Brandão AP: Role of
anthropometric indexes and blood pressure as determinants of left
ventricular mass and geometry in adolescents: The Rio de Janeiro Study.
Hypertension 1995, 26:1190-1194.
87. Hayman LL, Wiliams CL, Daniels SR, Steinberg J, Paridon S, Dennison BA:
Cardiovascular health promotion in the schools. Circulation 2004,
110:2266-2275.
88. Shahinfar S, Rippley R, Hogg RJ, et al: Multicenter study of enalapril
pharmacokinetics in hypertensive children and infants [abstract]. Pediatr
Res 2000, 47:473A.
89. Menon S, Berezny KY, Kilaru R, Benjamin DK Jr, Kay JD, Hazan L, Portman R,
Hogg R, Deitchman D, Califf RM, Li JS: Racial differences are seen in blood
pressure response to fosinopril in hypertensive children. Am Heart J
2006, 152(2):394-399.
90. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar SA: Double-blind, placebo-
controlled, dose-response study of the effectiveness and safety of
lisinopril for children with hypertension. Am J Hypertens 2003,
16(10):795-800.
91. Scheen AJ: Similar reduction in new cases of type 2 diabetes with
angiotensin receptor blocker and ACE inhibitor: comparison of meta-
analyses of prospective randomised trials. Rev Med Liege 2005, 60(5-
6):424-428.
92. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW,
Portman RJ, Falkner B: Efficacy and safety of extended release metoprolol
succinate in hypertensive children 6 to 16 years of age: a clinical trial
experience. Pediatr 2007, 150(2):134-139.
93. Bangalore S, Parkar S, Grossman E, Messerli FHA: A meta-analysis of 94,492
patients with hypertension treated with beta blockers to determine the
risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100(8):1254-62.
94. Libman I, Arslanian SA: Type II diabetes mellitus: no longer just adults.
Pediatr Ann 1999, 28:589-593.
95. Liese AD, D’Agostino RB Jr, Hamman RF, Kilgo PD, Lawrence JM, Liu LL,
Loots B, Linder B, Marcovina S, Rodriguez B, Standiford D, Williams DE: The
burden of diabetes mellitus among US youth: prevalence estimates
from the SEARCH for Diabetes in Youth Study. Pediatrics 2006,
118:1510-1518.
96. Ehtisham S, Hattersley AT, Dunger DB, Barrett TG: First UK survey of
paediatric type 2 diabetes and MODY. Arch Dis Child 2004, 89:526-529.
97. Ortega-Rodriguez E, Levy-Marchal C, Tubiana N, Czernichow P, Polak M:
Emergence of type 2 diabetes in an hospital based cohort of children
with diabetes mellitus. Diabetes Metab 2001, 27:574-578.
98. Rami B, Schober E, Nachbauer E, Waldhor T: Type 2 diabetes mellitus is
rare but not absent in children under 15 years of age in Austria. Eur J
Pediatr 2003, 162:850-852.
99. Schober E, Holl RW, Grabert M, Thon A, Rami B, Kapellen T, Seewi O,
Reinehr T: Diabetes mellitus type 2 in childhood and adolescence in
Germany and parts of Austria. Eur J Pediatr 2005, 164:705-707.
100. Herder C, Schmitz-Beuting C, Rathmann W, Haastert B, Schmitz-Beuting J,
Schafer M, Scherbaum WA, Schneitler H, Martin S: Prevalence of impaired
glucose regulation in German school-leaving students. Int J Obes (Lond)
2007, 31:1086-1088.
101. Mazza CS, Ozuna B, Krochik AG, Araujo MB: Prevalence of type 2 diabetes
mellitus and impaired glucose tolerance in obese Argentinean children
and adolescents. J Pediatr Endocrinol Metab 2005, 18:491-498.
102. Kitagawa T, Owada M, Urakami T, Yamauchi K: Increased incidence of non-
insulin dependent diabetes mellitus among Japanese schoolchildren
correlates with an increased intake of animal protein and fat. Clin Pediatr
(Phila) 1998, 37:111-115.
103. Silva ARV, Damasceno MMC, Carvalho ZMdF, Hissa MN, Almeida PC,
Silva LF: Prevalencia de factores de riesgo para diabetes mellitus tipo 2
en adolescentes de Fortaleza – Brasil. Enfermería Integral 2007, 7:11-14.
104. Carneiro IRI, Kushnir MC, Clemente ES, Brandão MG, Gomes MB: Obesidade
na adolescência: fator de risco para complicações clínico-metabolicas.
Arq Bras Endocrinol Metab 2000, 44:390-396.
105. Gungor N, Bacha F, Saad R, Janosky J, Arslanian S: Youth type 2 diabetes:
insulin resistance, beta-cell failure, or both? Diabetes Care 2005,
28:638-644.
106. Saad R, Gungor N, Arslanian S: Progression from normal glucose tolerance
to type 2 diabetes in a young girl: longitudinal changes in insulin
sensitivity and secretion assessed by the clamp technique and surrogate
estimates. Pediatr Diabetes 2005, 6:95-99.
107. Gungor N, Arslanian S: Progressive beta cell failure in type 2 diabetes
mellitus of youth. J Pediatr 2004, 144:656-659.
108. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC: UKPDS 26:
Sulphonylurea failure in non-insulin-dependent diabetic patients over
six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med
1998, 15:297-303.
109. Miller J: Type 2 diabetes in child and adolescent. In Pediatric
Endocrinology. Edited by: Lifshitz F. Marcel Dekker: New York; 2007:169-188.
110. Klein BE, Klein R, Moss SE, Cruickshanks KJ: Parental history of diabetes in
a population-based study. Diabetes Care 1996, 19:827-830.
111. Boney CM, Verma A, Tucker R, Vohr BR: Metabolic syndrome in childhood:
association with birth weight, maternal obesity, and gestational diabetes
mellitus. Pediatrics 2005, 115:e290-e296.
112. McCance DR, Pettitt DJ, Hanson RL, Jacobsson LT, Knowler WC, Bennett PH:
Birth weight and non-insulin dependent diabetes: thrifty genotype,
thrifty phenotype, or surviving small baby genotype? BMJ 1994,
308:942-945.
113. Carter JS, Pugh JA, Monterrosa A: Non-insulin-dependent diabetes
mellitus in minorities in the United States. Ann Intern Med 1996,
125:221-232.
114. Astrup A, Dyerberg J, Selleck M, Stender S: Nutrition transition and its
relationship to the development of obesity and related chronic diseases.
Obes Rev 2008, 9(Suppl 1):48-52.
115. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A: Changes in glucose
tolerance over time in women with polycystic ovary syndrome: a
controlled study. J Clin Endocrinol Metab 2005, 90:3236-3242.
116. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A:
Screening for abnormal glucose tolerance in adolescents with polycystic
ovary syndrome. J Clin Endocrinol Metab 2002, 87:1017-1023.
117. Brickman WJ, Holland JS, Silverman BL: Prevalence of postprandial
hyperglycemia in adolescents: a population-based study. Diabetes Care
2002, 25:1887-1888.
118. Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC,
Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R,
Shulman GI, Caprio S: Prediabetes in obese youth: a syndrome of
impaired glucose tolerance, severe insulin resistance, and altered
myocellular and abdominal fat partitioning. Lancet 2003, 362:951-957.
119. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ:
ISPAD Clinical Practice Consensus Guideline 2006-2007. Type 2 diabetes
mellitus in the child and adolescent. Pediatr Diabetes 2008, 9:512-526.
120. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV:
Impaired insulin action in puberty. A contributing factor to poor
glycemic control in adolescents with diabetes. N Engl J Med 1986,
315:215-219.
121. Ball GD, Huang TT, Gower BA, Cruz ML, Shaibi GQ, Weigensberg MJ,
Goran MI: Longitudinal changes in insulin sensitivity, insulin secretion,
and beta-cell function during puberty. J Pediatr 2006, 148:16-22.
122. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:
Report of the Expert Committee on the Diagnosis and Classification of
Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
123. Libman IM, Arslanian SA: Prevention and treatment of type 2 diabetes in
youth. Horm Res 2007, 67:22-34.
124. Hannon TS, Rao G, Arslanian SA: Childhood obesity and type 2 diabetes
mellitus. Pediatrics 2005, 116:473-480.
125. Invitti C, Guzzaloni G, Gilardini L, Morabito F, Viberti G: Prevalence and
concomitants of glucose intolerance in European obese children and
adolescents. Diabetes Care 2003, 26:118-124.
126. Wiegand S, Maikowski U, Blankenstein O, Biebermann H, Tarnow P,
Gruters A: Type 2 diabetes and impaired glucose tolerance in European
children and adolescents with obesity – a problem that is no longer
restricted to minority groups. Eur J Endocrinol 2004, 151:199-206.
127. Rosenbloom AL: Hyperglycemic crises and their complications in
children. J Pediatr Endocrinol Metab 2007, 20:5-18.
128. Bhowmick SK, Levens KL, Rettig KR: Hyperosmolar hyperglycemic crisis: an
acute life-threatening event in children and adolescents with type 2
diabetes mellitus. Endocr Pract 2005, 11:23-29.
129. Carchman RM, Dechert-Zeger M, Calikoglu AS, Harris BD: A new challenge
in pediatric obesity: pediatric hyperglycemic hyperosmolar syndrome.
Pediatr Crit Care Med 2005, 6:20-24.
Halpern et al. Diabetology & Metabolic Syndrome 2010, 2:55
http://www.dmsjournal.com/content/2/1/55
Page 19 of 20130. Cochran JB, Walters S, Losek JD: Pediatric hyperglycemic hyperosmolar
syndrome: diagnostic difficulties and high mortality rate. Am J Emerg
Med 2006, 24:297-301.
131. Sapru A, Gitelman SE, Bhatia S, Dubin RF, Newman TB, Flori H: Prevalence
and characteristics of type 2 diabetes mellitus in 9-18 year-old children
with diabetic ketoacidosis. J Pediatr Endocrinol Metab 2005, 18:865-872.
132. Matyka KA: Type 2 diabetes in childhood: epidemiological and clinical
aspects. Br Med Bull 2008, 86:59-75.
133. Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y,
Hellman R, Jellinger PS, Jovanovic LG, Levy P, Mechanick JI, Zangeneh F:
American Association of Clinical Endocrinologists medical guidelines for
clinical practice for the management of diabetes mellitus. Endocr Pract
2007, 13(Suppl 1):1-68.
134. Harwood K, Vuguin P, DiMartino-Nardi J: Current approaches to the
diagnosis and treatment of polycystic ovarian syndrome in youth. Horm
Res 2007, 68:209-217.
135. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ: Effect of
metformin in pediatric patients with type 2 diabetes: a randomized
controlled trial. Diabetes Care 2002, 25:89-94.
136. Glaser B, Cerasi E: Early intensive insulin treatment for induction of long-
term glycaemic control in type 2 diabetes. Diabetes Obes Metab 1999,
1:67-74.
137. Sellers EA, Dean HJ: Short-term insulin therapy in adolescents with type 2
diabetes mellitus. J Pediatr Endocrinol Metab 2004, 17:1561-1564.
138. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly
diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
139. Nathan DM: Glycemic management of type 2 diabetes: how tight is right
and how to get there. Arch Intern Med 2008, 168:2064-2066.
140. U.K. Prospective Diabetes Study Group: U.K. prospective diabetes study 16.
Overview of 6 years’ therapy of type II diabetes: a progressive disease.
Diabetes 1995, 44:1249-1258.
141. Bagust A, Beale S: Deteriorating beta-cell function in type 2 diabetes: a
long-term model. QJM. 2003, 96(4):281-288.
142. Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, Silink M,
Donaghue KC: Prevalence of diabetes complications in adolescents with
type 2 compared with type 1 diabetes. Diabetes Care 2006, 29:1300-1306.
143. Pinhas-Hamiel O, Zeitler P: Acute and chronic complications of type 2
diabetes mellitus in children and adolescents. Lancet 2007,
369:1823-1831.
144. Kershnar AK, Daniels SR, Imperatore G, Palla SL, Petitti DB, Pettitt DJ,
Marcovina S, Dolan LM, Hamman RF, Liese AD, Pihoker C, Rodriguez BL:
Lipid abnormalities are prevalent in youth with type 1 and type 2
diabetes: the SEARCH for Diabetes in Youth Study. J Pediatr 2006,
149:314-319.
145. Rodriguez BL, Fujimoto WY, Mayer-Davis EJ, Imperatore G, Williams DE,
Bell RA, Wadwa RP, Palla SL, Liu LL, Kershnar A, Daniels SR, Linder B:
Prevalence of cardiovascular disease risk factors in U.S. children and
adolescents with diabetes: the SEARCH for diabetes in youth study.
Diabetes Care 2006, 29:1891-1896.
146. Yokoyama H, Okudaira M, Otani T, Takaike H, Miura J, Saeki A, Uchigata Y,
Omori Y: Existence of early-onset NIDDM Japanese demonstrating severe
diabetic complications. Diabetes Care 1997, 20:844-847.
147. Zdravkovic V, Daneman D, Hamilton J: Presentation and course of Type 2
diabetes in youth in a large multi-ethnic city. Diabet Med 2004,
21:1144-1148.
148. Maahs DM, Snively BM, Bell RA, Dolan L, Hirsch I, Imperatore G, Linder B,
Marcovina SM, Mayer-Davis EJ, Pettitt DJ, Rodriguez BL, Dabelea D: Higher
prevalence of elevated albumin excretion in youth with type 2 than
type 1 diabetes: the SEARCH for Diabetes in Youth study. Diabetes Care
2007, 30:2593-2598.
149. Pavkov ME, Bennett PH, Knowler WC, Krakoff J, Sievers ML, Nelson RG:
Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage
renal disease and mortality in young and middle-aged Pima Indians. JA
MA2006, 296:421-426.
150. McGavock J, Sellers E, Dean H: Physical activity for the prevention and
management of youth-onset type 2 diabetes mellitus: focus on
cardiovascular complications. Diab Vasc Dis Res 2007, 4:305-310.
151. Nadeau KJ, Klingensmith G, Zeitler P: Type 2 diabetes in children is
frequently associated with elevated alanine aminotransferase. J Pediatr
Gastroenterol Nutr 2005, 41:94-98.
152. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S: Cardiovascular
risk factors and the metabolic syndrome in pediatric nonalcoholic fatty
liver disease. Circulation 2008, 118:277-283.
153. Levitt Katz LE, Swami S, Abraham M, Murphy KM, Jawad AF, McKnight-
Menci H, Berkowitz R: Neuropsychiatric disorders at the presentation of
type 2 diabetes mellitus in children. Pediatr Diabetes 2005, 6:84-89.
154. Reis JS, Alvarenga T, Rosario PW, Menezes PA, Rocha RS, Purisch S: Diabetes
mellitus associated with atypical antipsychotic medications: case report
and review of the literature. Arq Bras Endocrinol Metabol 2007, 51:488-493.
155. Buchholz S, Morrow AF, Coleman PL: Atypical antipsychotic-induced
diabetes mellitus: an update on epidemiology and postulated
mechanisms. Intern Med J 2008, 38:602-606.
doi:10.1186/1758-5996-2-55
Cite this article as: Halpern et al.: Metabolic syndrome, dyslipidemia,
hypertension and type 2 diabetes in youth: from diagnosis to
treatment. Diabetology & Metabolic Syndrome 2010 2:55.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Halpern et al. Diabetology & Metabolic Syndrome 2010, 2:55
http://www.dmsjournal.com/content/2/1/55
Page 20 of 20